



## Structured Administration and Supply Arrangement (SASA)

**TITLE:** Treatment of Sexually Transmissible Infection by Registered Nurses

**1. Authority:**

Issued by the Chief Executive Officer of Health under Part 6 of the Medicines and Poisons Regulations 2016.

**2. Scope:**

Authorises Registered Nurses working in a public health program to administer doses of antibiotics for treatment of a sexually transmissible infection.

**3. Criteria:**

This SASA authorises the actions specified in the table below.

<b>Practitioner:</b>	Registered Nurses who have completed training in accordance with Appendix 1.
<b>Practice setting:</b>	Public health programs operated or managed by a Health Service Provider of the WA Health system, or contracted entity, or a health service that is a member of the Aboriginal Health Council of Western Australia.  All regions of WA.
<b>Approved activity:</b>	Administration
<b>Approved medicines:</b>	Medicines listed as approved treatments in Appendix 2: <ul style="list-style-type: none"><li>• Oral azithromycin and ceftriaxone with lidocaine by deep intramuscular injection as a single treatment.</li><li>• Oral azithromycin, amoxicillin and probenecid as a single treatment.</li><li>• Oral azithromycin as a single treatment.</li><li>• Oral azithromycin, two doses, 12 to 24 hours apart.</li><li>• Benzathine benzylpenicillin by deep intramuscular injection as a single treatment.</li></ul>
<b>Medical conditions:</b>	Sexually transmissible infections in adults and mature minors aged 14 years or older: <ul style="list-style-type: none"><li>• chlamydia and/or gonorrhoea and/or syphilis confirmed by laboratory or point-of-care testing;</li><li>• syphilis (excluding neurosyphilis) of less than 2 years duration, or unknown duration, confirmed by laboratory testing or indicated by a reactive point-of-care test;</li><li>• empirical treatment of people presenting with symptoms consistent with infectious syphilis (excluding neurosyphilis) and/or uncomplicated urethritis and cervicitis syndromes consistent with chlamydia and/or gonorrhoea</li><li>• asymptomatic people presenting as known contacts of a person confirmed with chlamydia and/or gonorrhoea and/or syphilis.</li></ul>

#### 4. Conditions:

The administration of approved medicines under this SASA is subject to the conditions that:

- a. Patient selection, administration and follow up care is in accordance with the *Guidelines for managing sexually transmissible infections and blood-borne viruses* (The Silver Book) and Appendix 2;
- b. Administration is not repeated for the same instance of the condition, without the direction of a medical practitioner, credentialed for a public health STI program by a Health Service Provider of the WA Health system, or other entity under which this SASA is being applied;
- c. The medicines are procured by an authorised person or an appropriate Medicines and Poisons Permit holder;
- d. Procurement and storage of the approved medicines is in accordance with Part 9 of the Medicines and Poisons Regulations 2016;
- e. Record keeping of administration is in accordance with Part 12 of the Medicines and Poisons Regulations 2016;
- f. Laboratory confirmed diagnosis of chlamydia and/or gonorrhoea and/or syphilis must be notified to the Director, Communicable Disease Control Directorate, Department of Health, via the local Public Health Unit by post, telephone or facsimile, preferably within 24 hours; and,
- g. Notification must comply with the Procedure for Notification of Communicable Diseases (Excluding HIV/AIDS) and be in an approved notification format.

#### 5. References:

- a. *Guidelines for managing sexually transmissible infections and blood-borne viruses*. Available at: <http://ww2.health.wa.gov.au/Silver-book>
- b. Communicable Disease Control Directorate. *Notification of Communicable Diseases*. Available at: <http://ww2.health.wa.gov.au/Silver-book/STI-or-HIV-notification>

#### 6. Issued by:

<b>Name:</b>	Dr Andrew Robertson
<b>Position:</b>	Chief Health Officer
<b>Date:</b>	2 December 2025

---

Enquiries to:	Medicines and Poisons Regulation Branch	Number:	006/6-2025
	MPRB@health.wa.gov.au	Date:	2 December 2025

---

## **APPENDIX 1**

---

### **Approved Training**

---

All Registered Nurses administering a medicine in accordance with this SASA must have successfully completed a course of training approved by the Chief Executive Officer of the Department of Health or an equivalent course provided by a Registered Training Organisation (RTO) or a university and must maintain their competency through updates and/or completion of training every two years.

Approved courses must require participants to demonstrate satisfactory knowledge, understanding and minimum competencies in the following areas:

- a. Sexual health history taking;
- b. Sexual health and STI clinical assessment;
- c. Pathology testing, including request and collecting samples;
- d. Contraindications and adverse effects of the medicines authorised for administration;
- e. STI health promotion and education;
- f. STI contact tracing;
- g. Communicable disease notification and referral; and
- h. Reporting of suspected child sexual abuse.

## APPENDIX 2

### Approved treatments and treatment recommendations

#### Approved treatments

Treatment	Agent		Dosage	Route	Frequency
Azithromycin 1 gram	Azithromycin		1 gram	oral	single dose
Azithromycin 2 grams	Azithromycin		2 grams (1 gram x 2 doses)	oral	1 gram, then another 1 gram 12 to 24 hours later
ZAP pack	Azithromycin	with and	1 gram	oral	single dose
	Amoxicillin		3 gram		
	Probenecid		1 gram		
LAC pack	Azithromycin	with	1 gram	oral	single dose
	Ceftriaxone with lidocaine 1%		500 mg in 2 ml	deep intramuscular injection	
Azithromycin + Ceftriaxone with lidocaine	Azithromycin	with	2 grams	oral	single dose
	Ceftriaxone with lidocaine 1%		500 mg in 2 ml	deep intramuscular injection	
Benzathine benzylpenicillin	Benzathine benzylpenicillin		2,400,000 units <sup>1</sup>	deep intramuscular injection, 1,200,000 units on each side	single dose

<sup>1</sup> Note: 900 mg benzathine benzylpenicillin = 1,200,000 units = 1016.6 mg benzathine benzylpenicillin tetrahydrate

## Treatment recommendations

Client		STI acquired in	Treatment
Empirical treatment of symptomatic clients	Uncomplicated urogenital gonorrhoea + / - chlamydia	Kimberley	ZAP
		Rest of WA and elsewhere	LAC
	Infectious syphilis	Anywhere	Benzathine benzylpenicillin
Laboratory or Point-of-Care testing confirmed cases	Uncomplicated urogenital or rectal gonorrhoea	Kimberley	ZAP
		Rest of WA and elsewhere	LAC
	Uncomplicated pharyngeal gonorrhoea	Kimberley	ZAP + Azithromycin 1 gram
		Rest of WA and elsewhere	Azithromycin + Ceftriaxone with lignocaine
	Uncomplicated urogenital or pharyngeal chlamydia	Goldfields, Kimberley, Pilbara	Azithromycin 1 gram
		Rest of WA and elsewhere	<a href="#">Doxycycline<sup>2</sup></a>
	Uncomplicated asymptomatic rectal chlamydia	Goldfields, Kimberley, Pilbara	Azithromycin 2 grams
		Rest of WA and elsewhere	<a href="#">Doxycycline<sup>2</sup></a>
	Infectious syphilis	Anywhere	Benzathine benzylpenicillin
Asymptomatic sexual partners of confirmed cases	Chlamydia	Goldfields, Kimberley, Pilbara	Azithromycin 1 gram
		Rest of WA and elsewhere	<a href="#">Doxycycline<sup>2</sup></a>
	Gonorrhoea	Kimberley	ZAP
		Rest of WA and elsewhere	LAC
	Infectious syphilis	Anywhere	Benzathine benzylpenicillin

## Treatment notes

<sup>2</sup> Doxycycline **must** be prescribed by an authorised prescriber (medical practitioner or nurse practitioner) and either supplied by the prescriber or dispensed at a pharmacy. This SASA does not authorise Registered Nurses, who are not endorsed as a Nurse Practitioner to supply doxycycline.

- Consent to treatment should be obtained, as required, in accordance with local organisational policy.
- Clients should be advised of expected adverse events and provided with a treatment fact sheet - <http://ww2.health.wa.gov.au/Patient-fact-sheets>.
- For clients with a history of allergy to any component of treatment, or other contraindication - do not administer treatment - seek further advice from a medical practitioner.
- For management of any reported adverse events - seek further advice from a medical practitioner.
- Clients should be directly observed while taking oral doses.
- Cases of syphilis of unknown duration are to be referred to a medical practitioner for ongoing, individual management after the first dose of benzathine benzylpenicillin has been administered